Cancer glossary
Disease progression on a CT report: what it means and what comes next
Progressive disease (PD) means growth beyond the RECIST 1.1 threshold or new lesions. How it is defined, how it differs from pseudoprogression, what is next.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026
In short
Progression (progressive disease, PD) means tumor growth beyond a set threshold, or new lesions, during treatment or follow-up. It usually means the current treatment is no longer holding the cancer back and changes need to be discussed.
How it appears in your report
- “Interval worsening: increase in the size of lesions…”.
- “New lesions in the liver”.
- “RECIST 1.1 response: progressive disease (PD)”.
- In an oncologist’s letter: “disease progression”, “progression on … line of therapy”.
“Worsening” in a radiologist’s description is not always formal progression: what matters is whether the threshold has been reached.
What it means
Under RECIST 1.1, progression is called in either of these cases:
| Criterion | What is counted |
|---|---|
| Growth in the sum of target lesion diameters | At least 20% from the smallest sum on treatment and at least 5 mm in absolute terms |
| A new lesion | Even if the others have shrunk |
Growth is measured from the smallest sum, not from baseline. Slight growth that does not reach the threshold is still stable disease.
Progression is not only about scans. Doctors speak of clinical progression when your condition clearly worsens because of the cancer. A rise in tumor markers without confirmation on imaging is usually not counted as progression by itself. On immunotherapy, the first “progression” sometimes turns out to be pseudoprogression, so it may be confirmed with a repeat scan.
Does it affect treatment
Yes, it is one of the main reasons to review the plan. Usually the options discussed are moving to the next line of therapy, sometimes local treatment of one growing lesion if the others are controlled, or joining a clinical trial. The choice depends on the tumor type, previous treatment and your condition, and the decision is made by your treating doctor or a tumor board. If you want to check that enough options have been considered, I can review your records as a second opinion.
Questions to ask your doctor
- Is this progression by RECIST or a descriptive worsening?
- Does it need confirming with a repeat scan or a biopsy of the new lesion?
- What treatment options are there next, and what does each one offer?
Sources
- RECIST 1.1 — RECIST Working Group / EORTC; Eisenhauer E.A. et al., European Journal of Cancer, 2009
- Response evaluation criteria in solid tumours (RECIST) — Radiopaedia
- iRECIST guidelines — RECIST Working Group / EORTC, 2017
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
